N-Acetyl Cysteine in Trichotillomania
This is a 12-week, double-blind study of N-Acetyl Cysteine in the treatment of trichotillomania
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Trichotillomania|
- Massachusetts General Hospital Hairpulling Scale [ Time Frame: Beginning to end of study every 2 weeks. ] [ Designated as safety issue: No ]There is no minimum or maximum score to quantify 'good' or 'poor' improvement based on this scale. The total score can range from 0-28 with zero being no problems to 28 being the most severe score one can receive.A total of 6 assessments were made, however only the final score was reported here to show the final outcome measure that was used in the final report of possible improvement and what was reported for final publication of data.
|Study Start Date:||July 2006|
|Study Completion Date:||September 2008|
|Primary Completion Date:||September 2008 (Final data collection date for primary outcome measure)|
Active Comparator: N-Acetyl Cysteine
Drug: N-Acetyl Cysteine
600mg capsules in varying doses for 12 weeks.
Other Name: NAC
Placebo Comparator: 2
The goal of the proposed study is to evaluate the efficacy and safety of N-Acetyl Cysteine (NAC) in trichotillomania. Forty subjects with DSM-IV trichotillomania will receive 12 weeks of double-blind NAC or placebo. The hypothesis to be tested is that NAC will be effective and well tolerated in patients with trichotillomania compared to placebo. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00354770
|United States, Minnesota|
|University of Minnesota Medical Center|
|Minneapolis, Minnesota, United States, 55454|
|Principal Investigator:||Jon E Grant, MD, JD||University of Minnesota - Clinical and Translational Science Institute|